Erik Engellau-Nilsson

Blykalla is on a mission to change the energy future of the world, by providing green, safe, baseload energy through next generation small modular lead-cooled reactors. Blykalla is a Swedish deep-tech company founded in 2013 by Janne Wallenius, Peter Szakalos and Jesper Ejenstam as a spin-off from the Royal Institute of Technology in Stockholm, where Janne Wallenius carried out research on design and safety analysis on lead-cooled reactor systems since 1996. We develop and build lead-cooled small modular reactors (SMRs) to deliver safe, scalable and carbon-free baseload power supply. Thanks to lead-cooling, we achieve high safety in a very compact format, allowing for a simple and cost effective design that can be mass produced. Our unique reactor design will provide safe and green baseload energy that is a perfect complement to solar and wind power.

Cellcolabs mission is to prevent and treat diseases by making high quality stem cells available and affordable. We do that by industrial scale production and collaborations.

ABC Labs is a technology-native care provider, diagnostics lab, biobank, and research organisation. Creating unified, exponentially improving, public health products. We are innovating at the frontier of diagnostics by combining software, robotics, data science, medical consultation, lab automation, and operational excellence to create end-to-end products that span the entire spectrum of user needs — and become exponentially more efficient over time. Founded as an impact project during the pandemic, ABC grew into Sweden’s largest COVID-19 testing lab, conducting up to 28% of national testing. Our R&D efforts have led to three national screening programs and nine publications. We are now applying this infrastructure to a new frontier: substance abuse testing at workplaces — a complex, highly regulated, and fragmented value chain growing at >10% CAGR across Europe and the U.S., and in urgent need of scalable, intelligent solutions. In parallel, we are building a research project utilizing long term multi-omics and biochemistry data to answer fundamental questions about health and human biology, an initiative we believe can become one of the most impactful scientific endeavors in the decade to come.

29k is a non profit tech start up on a mission to make transformational growth available to everyone. We merge science and technology to scale positive psychology, helping people to grow what we call the super skills of the 21st century: Curiosity, Perspective Taking, Empathy, Sense-making and Self-Determination.

Vinnova is Sweden’s innovation agency. Our mission is to promote sustainable growth by improving the conditions for innovation, as well as funding needs-driven research. Vinnova’s vision is for Sweden to be a world-leading country in research and innovation, an attractive place in which to invest and conduct business. We promote collaborations between companies, universities, research institutes and the public sector. We do this by stimulating a greater use of research, by making long-term investment in strong research and innovation milieus and by developing catalytic meeting places. Vinnova’s activities also focus on strengthening international cooperation. In order to increase our impact, we are also dedicated to interacting with other research financiers and innovation-promoting organisations. Every year Vinnova invests about SEK 2 billion in various initiatives. Vinnova is a Swedish government agency working under the Ministry of Enterprise, Energy and Communications and acts as the national contact agency for the EU Framework Programme for R&D. We are also the Swedish government’s expert agency within the field of innovation policy. Vinnova was founded in January 2001. About 200 people work here and we have offices in Stockholm and Brussels. Our Director General is Charlotte Brogren.

Blykalla is on a mission to change the energy future of the world, by providing green, safe, baseload energy through next generation small modular lead-cooled reactors. Blykalla is a Swedish deep-tech company founded in 2013 by Janne Wallenius, Peter Szakalos and Jesper Ejenstam as a spin-off from the Royal Institute of Technology in Stockholm, where Janne Wallenius carried out research on design and safety analysis on lead-cooled reactor systems since 1996. We develop and build lead-cooled small modular reactors (SMRs) to deliver safe, scalable and carbon-free baseload power supply. Thanks to lead-cooling, we achieve high safety in a very compact format, allowing for a simple and cost effective design that can be mass produced. Our unique reactor design will provide safe and green baseload energy that is a perfect complement to solar and wind power.

We work with world-class researchers and scientists to industrialise, commercialize and scale innovations that can fundamentally transform the future for people and the planet. Launcher offers access to impact capital, world-class recruitments and scalable growth structure.

Cellcolabs mission is to prevent and treat diseases by making high quality stem cells available and affordable. We do that by industrial scale production and collaborations.

ABC Labs is a technology-native care provider, diagnostics lab, biobank, and research organisation. Creating unified, exponentially improving, public health products. We are innovating at the frontier of diagnostics by combining software, robotics, data science, medical consultation, lab automation, and operational excellence to create end-to-end products that span the entire spectrum of user needs — and become exponentially more efficient over time. Founded as an impact project during the pandemic, ABC grew into Sweden’s largest COVID-19 testing lab, conducting up to 28% of national testing. Our R&D efforts have led to three national screening programs and nine publications. We are now applying this infrastructure to a new frontier: substance abuse testing at workplaces — a complex, highly regulated, and fragmented value chain growing at >10% CAGR across Europe and the U.S., and in urgent need of scalable, intelligent solutions. In parallel, we are building a research project utilizing long term multi-omics and biochemistry data to answer fundamental questions about health and human biology, an initiative we believe can become one of the most impactful scientific endeavors in the decade to come.